BioCentury | Mar 25, 2020
Deals

AstraZeneca, Silence partner to bring siRNA therapies to extrahepatic tissues

Thirteen years after they first teamed up, AstraZeneca and Silence are giving their partnership another shot with a new $80 million deal to develop siRNA therapeutics targeting the liver and extrahepatic tissues. The deal is...
BioCentury | Mar 4, 2020
Product Development

Biopharma broadens fight vs. COVID-19 as Alnylam, Takeda unveil new programs

The biopharma industry is bringing additional modalities into the fight against COVID-19, with Vir and Alnylam developing an siRNA therapeutic while Takeda adds a plasma-based approach from COVID-19 survivors. Both programs will broaden and potentially...
BioCentury | Dec 17, 2019
Clinical News

Alnylam’s lumasiran is latest RNAi therapeutic to hit pivotal study goal

Lumasiran’s success in a pivotal study to treat a form of hyperoxaluria represents another step toward Alnylam meeting its updated goal of having four approved medicines by the end of 2020 -- all since the...
BioCentury | Nov 22, 2019
Company News

Alnylam outlines ambitions, pipeline progress at R&D day

In its R&D day presentation Friday, Alnylam outlined its goals of becoming a self-sustaining company with at least eight approved drugs and 10 late-stage clinical candidates by 2025, with safer GalNAc conjugates, a late-stage amyloidosis...
BioCentury | Jun 25, 2019
Preclinical News

Alnylam preclinical data latest sign companies still plugging away at oral oligos

Proof-of-concept mouse data from Alnylam suggests the company has found a formulation that supports oral delivery of its oligonucleotide therapy, a long-standing goal in the field that has produced splashy deals but few clinical results....
BioCentury | May 3, 2019
Product Development

With a deal and a debut, targeted oligo delivery gets a boost from ADCs

The marriage of antibody-drug conjugates and oligonucleotides won two votes of confidence last month with a deal between Lilly and Avidity, and the debut of Atlas-backed Dyne Therapeutics. The approach promises delivery of oligos to...
BioCentury | Mar 28, 2019
Translation in Brief

Tuning metabolism in liver organoids

An Alnylam-MIT collaboration has used RNAi technology to tune enzyme expression in hepatocyte-based organoids to better model drug metabolism during tox screens. The collaboration with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) built on a series of papers...
BioCentury | Jan 31, 2019
Emerging Company Profile

Apic: Dual-gene therapies

Apic Bio Inc.'s APB-101 is a dual-function gene therapy for AAT deficiency that silences the mutant AAT gene and augments wild-type AAT expression, which the company believes gives it greater efficacy and lower liver toxicity...
BioCentury | Dec 14, 2018
Financial News

Janssen veterans raise $13M for Centyrin platform

Aro Biotherapeutics Co. (Philadelphia, Pa.) unveiled the lead programs from its Centyrin pipeline on Dec. 11, along with a $13 million seed round from Johnson & Johnson Innovation - JJDC Inc. and BioMotiv LLC (Cleveland, Ohio)....
BioCentury | Dec 11, 2018
Financial News

Janssen veterans raise $13M for Centyrin platform

Aro Biotherapeutics Co. (Philadelphia, Pa.) unveiled the lead programs from its Centyrin pipeline Tuesday, along with a $13 million seed round from Johnson & Johnson Innovation - JJDC Inc. and BioMotiv LLC (Cleveland, Ohio). Former Johnson...
Items per page:
1 - 10 of 112